Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.
暂无分享,去创建一个
Qianjun Li | H. Wakimoto | R. Martuza | J. Buolamwini | S. Rabkin | Y. Yen | Chin-Lee Wu | B. Passer | Bingsen Zhou | J. Noah | Shu-Lin Wu | Tooba A. Cheema | C. Zaupa | J. Sarte | M. Razmjoo | Shulin Wu | Cécile Zaupa
[1] C. Kevil,et al. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. , 2010, Cardiovascular research.
[2] R. Martuza,et al. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures , 2009, Gene Therapy.
[3] R. Martuza,et al. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells , 2009, Cancer Gene Therapy.
[4] Khalid Shah,et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. , 2009, Cancer research.
[5] D. Kirn,et al. Development of targeted oncolytic virotherapeutics through translational research , 2008 .
[6] T. Chou,et al. Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer , 2008, Clinical Cancer Research.
[7] Hyung-Hwan Kim,et al. Translational therapeutics of dipyridamole. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[8] J. Buolamwini,et al. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. , 2007, Journal of medicinal chemistry.
[9] P. Philip,et al. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Stephen A Baldwin,et al. Nucleoside transporters: from scavengers to novel therapeutic targets. , 2006, Trends in pharmacological sciences.
[11] H. Fukuhara,et al. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. , 2005, Cancer research.
[12] Prasad Adusumilli,et al. Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] Lijun Xue,et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. , 2003, Cancer research.
[14] K. Delman,et al. Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus , 2001, Journal of Virology.
[15] R. Martuza,et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[17] S. Yao,et al. Cloning of a human nucleoside transporter implicated in the Cellular uptake of adenosine and chemotherapeutic drugs , 1997, Nature Medicine.
[18] S. Elledge,et al. Ribonucleotide reductase: regulation, regulation, regulation. , 1992, Trends in biochemical sciences.
[19] D M Coen,et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.
[20] B. Roizman,et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. , 1990, Science.